A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease

Lock, Kevin; Wilson, Koo; Murphy, Daniel; Riesco, Juan Antonio

doi:10.1517/14656566.2011.628935

Cited by 17 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the models (n ¼ 40) were developed for the purpose of economic evaluation, either of alterative COPD treatments or of a COPD management program [13][14][15][16][17][18][19][20][21][22][24][25][26][27][28][30][31][32][33][34][37][38][39][42][43][44][45][46][47][48][49][50][51][52][54][55][56]58,60,61]. Two models [40,41] were developed to project the future burden of COPD; five models [23,29,35,36,53] represented a case study for methodological work; and two models [57,59] were developed as a generic modeling framework (multipurpose and n...…”

Section: Summary Of General Characteristics Of Models and Their Adhermentioning

confidence: 99%

A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Summary Of General Characteristics Of Models and Their Adhermentioning

confidence: 99%

A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A study with a similar structure to those previously mentioned, conducted in patients with chronic obstructive pulmonary disease (COPD) [29] in Spain, Germany, United ed in the first year) is less than 1.85% of the Class A public pharmaceutical expenditure [34], and less than 0.002% of the national public health expenditure, without even considering any wholesale discounts.…”

Section: Sensitivity Analysismentioning

confidence: 99%

Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

Spandonaro

Mancusi²,

Polistena

2017

View full text Add to dashboard Cite

INTRODUCTION: The promotion of smoking cessation is a worldwide Public Health priority. OBJECTIVE: To estimate the budget impact on the Italian National Health Service (NHS) of the access to reimbursement of varenicline for the treatment of high risk patients with bronchopulmonary, diabetic and cardiovascular diseases. METHODS: A closed-group Markov model was developed in order to compare the costs incurred by the NHS to promote smoking cessation with cessation-related savings, using an alternative scenario in which aids to cessation are not reimbursed by the NHS. The analysis was conducted over a 5-year time horizon, in the perspective of the Italian NHS. Efficacy was expressed in terms of smoke abstinence for at least one year, and data was derived from clinical trials; the savings associated with smoking cessation were derived from cost-of-illness studies. RESULTS: The results show how costs would concentrate in the first year: they are estimated at € 200.6 million, of which € 162.4 million for drug therapy and € 38.2 million for counseling. Average annual savings over the first five years are estimated at € 77.7 million, with a cumulative net impact at 5 years of € -188.0 million (cost-saving). The analysis appears to be robust: sensitivity analyses show that the covering of initial costs occurs in any case between the third and fourth year, and that the treatment remains cost-saving at 5 years. CONCLUSIONS: The financial impact on the Italian NHS of the reimbursement of varenicline for the treatment of high risk smoking population would be a sustainable healthcare policy, resulting in cost savings starting from the fourth year.

show abstract

“…Untreated illness frequently leads to lower quality of life, loss of productivity, and increased health care expenditures for hospitalization, emergency room treatment, family care, and doctor visits (Goldie et al 2004 ). Effective pharmacotherapy often substantially lowers total health care costs for groups of patients (Arnold 2007 ;Lock et al 2011 ) and can drive marked improvement in the quality of life for those patients and their families. The evaluation of drug pricing considers principles of both macroeconomics and humanity.…”

Section: Basics Of Pricingmentioning

confidence: 99%

Pharmacoeconomic Considerations in CNS Drug Development

Gray

2013

Drug Delivery to the Brain

View full text Add to dashboard Cite

Recent advances in understanding of the blood-brain barrier (BBB) suggest that we are entering an era in which basic discoveries of BBB structure and function may be parlayed into meaningful disease applications. The development of impactful human therapies is a diffi cult and lengthy process; nonetheless, many researchers desire to see their work applied to the treatment of human disease. Signifi cant fi nancial reward will follow functional solutions to BBB delivery challenges; however, validating a trans-BBB delivery strategy to support and sustain a clinical program is costly and risky and requires multidisciplinary expertise. Investigators must necessarily garner funding and expertise for such campaigns, mainly through government grants, private investment fi rms, and industrial partnerships. Among the many considerations for researchers looking to advance brain delivery technology are the commercial aspects of the technology and the requirements attached to the funding mechanisms for clinical development. Early choices about delivery modality and target therapy (indication) have important consequences for the development process. An understanding of the forces that currently drive the pricing of therapeutics and the factors considered by potential investors who can fund expensive clinical development programs is helpful for framing a discussion about the pharmacoeconomics of BBB delivery. Complex multimodal delivery technologies may have added challenges for demonstrating safety and signifi cantly higher drug manufacturing costs that can infl uence the risk-benefi t analysis made by potential investors. Both the therapeutic application and the delivery system infl uence the path to generating commercial or government interest in advancing a particular brain delivery approach toward the clinic.

show abstract

A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease

Abstract: Varenicline is expected to be a cost-effective aid to smoking cessation in COPD patients in all of the countries studied.

Cited by 17 publications

References 36 publications

A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease

A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease

Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

Pharmacoeconomic Considerations in CNS Drug Development

Contact Info

Product

Resources

About